Bristol-Myers Squibb Medical Imaging of North Billerica, MA, touted its line of radiopharmaceutical products at the Society of Nuclear Medicine (SNM) show, as well as its support for SNM's "Bench to Bedside" program.
A key focus for the company was its Cardiolite technetium-99m agent for nuclear cardiology studies, and it also emphasized its TechneLite technetium-99m radiopharmaceutical and thallium, gallium, and xenon products.
Bristol-Myers Squibb is also a member of the Corporate Circle for the Bench to Bedside program, announced at this year's SNM show as an effort to promote molecular imaging through education, training, and advocacy.
By AuntMinnie.com staff writers
June 7, 2006
Related Reading
Bristol-Myers Squibb gets Premier contract, April 21, 2006
Bristol-Myers Squibb, Thermocore partner, November 19, 2004
Bristol-Myers Squibb, Adenosine begin phase II trials, March 24, 2004
Kereos, Bristol-Myers Squibb to collaborate in molecular imaging, March 3, 2004
Fujisawa, Bristol-Myers Squibb ink promotion deal, October 21, 2003
Copyright © 2006 AuntMinnie.com
